Axsome Therapeutics (AXSM) Misses Q4 EPS by 58c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($1.54), $0.58 worse than the analyst estimate of ($0.96). Revenue for the quarter came in at $117.32 million versus the consensus estimate of $117.69 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Cinema United: issues joint letter to state AGs and Paramount
• OpenAI pauses frontier model training to strengthen safeguards
• Boeing-Lockheed space venture inks $1.5 billion private bonds - Bloomberg